

# AccelTRA™ Component Case Study

## Reducing Lead Time & Optimizing Costs

### The Situation

Because of competitive pressures, generic manufacturers are under considerable influence to get their products to market quickly. With significantly higher quality expectations from regulators, and the need to ensure the quality and safety of medical products for patients, fast commercialization of a new generic drug product can be a challenge. To meet these increasing quality standards and ensure a quick move to market, emerging generics injectable manufacturers needed flexibility and simplicity when dealing with drug containment and delivery.

### The Challenge

Seeking to reduce lead time and optimize costs, a generic drug manufacturer reached out to West to learn more about the AccelTRA™ component platform. The company hoped to reduce the number of its elastomer SKUs by developing a deeper understanding of the AccelTRA component's applicability to, and suitability with, its current drug product offerings and upcoming product lines. In addition, the company was open to exploring how a commitment to purchase a greater volume of a single formulation could reduce costs by enabling the reduction of the company's on-hand inventory.

### The Solution

From the beginning, the company was skeptical yet hopeful of the value they could realize by selecting AccelTRA components. Upon learning that the AccelTRA component program provided robust extractables data and optimized lead times for both samples and commercial quantities, the company realized not only a six-week time savings associated with component testing, but also a significant reduction in elastomer SKUs. West Technical Services experts analyzed the company's molecular entities to understand which drug products would work best with AccelTRA components. Detailed analysis found a 95% match with the company's existing product lines. Because of this analysis, as well as the continued technical support provided by West experts and the potential cost savings, the company went ahead with its use of the AccelTRA component 4031 formula elastomers for the original drug product line's containment needs, and is now considering expanding its use of AccelTRA components for other product lines. Use of the AccelTRA component platform – including components, extractables data and collaboration with West's technical experts – helped the customer realize significant savings, reduce elastomer SKU complexity, and increase speed to market.

